Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | type A flavoprotein, putative | 0.0202 | 0.1463 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0528 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0528 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0528 | 1 | 1 |
Echinococcus multilocularis | methionine synthase reductase | 0.0326 | 0.4712 | 0.4712 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0528 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0528 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0528 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0528 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0528 | 1 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0468 | 0.8428 | 0.8159 |
Loa Loa (eye worm) | AGC/DMPK/ROCK protein kinase | 0.0454 | 0.8059 | 0.7726 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0202 | 0.1463 | 0.5 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0468 | 0.8428 | 0.8159 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0202 | 0.1463 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0468 | 0.8428 | 0.5 |
Echinococcus granulosus | methionine synthase reductase | 0.0326 | 0.4712 | 0.4712 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0528 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0528 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0528 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0326 | 0.4712 | 0.5 |
Brugia malayi | Protein kinase domain containing protein | 0.0454 | 0.8059 | 0.7726 |
Onchocerca volvulus | 0.0146 | 0 | 0.5 | |
Leishmania major | cytochrome P450 reductase, putative | 0.0468 | 0.8428 | 0.8159 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0528 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0468 | 0.8428 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0326 | 0.4712 | 0.3805 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0202 | 0.1463 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0528 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0528 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0528 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0266 | 0.314 | 0.314 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0262 | 0.3035 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0326 | 0.4712 | 0.3805 |
Leishmania major | p450 reductase, putative | 0.0528 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0528 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0528 | 1 | 0.5 |
Schistosoma mansoni | diflavin oxidoreductase | 0.0262 | 0.3035 | 0.3035 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0528 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0262 | 0.3035 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0528 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0528 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0326 | 0.4712 | 0.4712 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0528 | 1 | 1 |
Treponema pallidum | flavodoxin | 0.0202 | 0.1463 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0202 | 0.1463 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.